GDD-261
GDD-261 is an orally active potent allosteric PHGDH inhibitor with IC50 of 61 nM and KD of 1.17 μM. GDD-261 potently suppresses de novo serine biosynthesis via blocking the rate-limiting catalytic activity of PHGDH, elevates intracellular reactive oxygen species (ROS) and γ-H2AX levels, and reduces the GSH/GSSG ratio to trigger tumor cell oxidative stress and DNA damage. GDD-261 mainly applies to research on Erlotinib (HY-50896)-resistant EGFR-mutant non-small cell lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C24H16ClF3N4O4S2
- Molecular Weight:580.99
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
PHGDH 0.061 μM (IC50) |
PHGDH 1.17 μM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SW837 | IC50 |
8.54 μM
|
Inhibits SW837 cells growth for 72 h
Inhibits SW837 cells growth for 72 h
|
42263187 |
| HCT-116 | IC50 |
15.28 μM
|
Inhibits HCT-116 cells growth for 72 h
Inhibits HCT-116 cells growth for 72 h
|
42263187 |
| SW-620 | IC50 |
18.92 μM
|
Inhibits SW-620 cells growth for 72 h
Inhibits SW-620 cells growth for 72 h
|
42263187 |
| J82 | IC50 |
14.76 μM
|
Inhibits J82 cells growth for 72 h
Inhibits J82 cells growth for 72 h
|
42263187 |
| A375-SM | IC50 |
22.9 μM
|
Inhibits A75 cells growth for 72 h
Inhibits A75 cells growth for 72 h
|
42263187 |
| Malme-3M | IC50 |
30.45 μM
|
Inhibits Malme-3M cells growth for 72 h
Inhibits Malme-3M cells growth for 72 h
|
42263187 |
| SK-HEP1 | IC50 |
32.63 μM
|
Inhibits SK-HEP1 cells growth for 72 h
Inhibits SK-HEP1 cells growth for 72 h
|
42263187 |
In Vitro
GDD-261 (120 min) exhibits broad inhibitory effects across PHGDH-overexpressing tumor cell lines[1].
GDD-261 (1-10 μM; 1-6 h) results in a dose-dependent reduction in M+3 serine levels compared to the control, indicating effective suppression of de novo serine synthesis in MDA-MB-468 and PC9ER4 cells[1].
GDD-261 (3 days) exhibits significantly higher inhibitory activity against PC9ER4 (IC50=7.72 μM) compared with HCC827ER9 (IC50=28.47 μM)[1].
GDD-261 (2.5-5 μM; 3 days) alone exhibits comparable antiproliferative activity against PC9 and PC9ER4 cells[1].
GDD-261 (5-10 μM; 6 days) exhibits synergistic activity with Erlotinib in PC9ER4 cells via PHGDH inhibition[1].
GDD-261 (10 μM; 24 h) minimally affects EGFR phosphorylation or the downstream ERK and AKT signaling alone[1].
GDD-261 (3-20 μM; 72 h) induces DNA damage and triggers apoptosis in Erlotinib-resistant cells in a dose-dependent manner[1].
GDD-261 (1-10 μM; 1 h) induces oxidative stress in PC9 and PC9ER4 cells by altering GSH/GSSG levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC9 and PC9ER4 cells
-
Concentration:2.5 μM, 5 μM
-
Incubation Time:3 days
-
Result:Displayed equivalent antiproliferative potency against PC9 and PC9ER4 cells alone.
-
Cell Line:PC9ER4 cells
-
Concentration:5 μM, 7.5 μM, 10 μM
-
Incubation Time:6 days
-
Result:Combined with Erlotinib markedly increased antiproliferative efficacy against resistant cells.
Showed synergy with Erlotinib only in PHGDH-proficient cells, and this combinatorial benefit vanished after PHGDH knockdown.
-
Cell Line:PC9ER4 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Had virtually no effect on the protein levels of p-EGFR, p-AKT, and p-ERK.
-
Cell Line:PC9ER4 cells
-
Concentration:3 μM, 10 μM, 20 μM
-
Incubation Time:72 h
-
Result:Increased γH2AX protein levels in a dose-dependent manner.
Increased cleaved caspase-3 protein levels in a dose-dependent manner.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-nude mice were injected 0.2 mL containing 5 × 106 PC9ER4 cells[1]
-
Dosage:25 mg/kg, 50 mg/kg combined with Erlotinib at 30 mg/kg
-
Administration:p.o., twice per day (Erlotinib for once daily), for 20 days
-
Result:Exerted dose-dependent suppression of tumor volume and weight when combined with Erlotinib.
Exerted no significant influence on mouse body weight when combined with Erlotinib.
Caused no evident pathological lesions in major organs including the liver, spleen and kidney of treated mice.
Chemical Information
-
Molecular Weight 580.99
-
Formel C24H16ClF3N4O4S2
-
SMILES
FC(C(NC1=CC=C(C(Cl)=C1)NS(C2=CC=C(C=C2)C(NC3=NC(C4=CC(F)=CC=C4)=CS3)=O)(=O)=O)=O)F
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)